Reasons for excluding adverse events in cost-effectiveness analyses of vaccines: A survey amongst authors

Although vaccines must adhere to the strictest safety standards in medicine, adverse events (AE) do occur occasionally. Even when clinically negligeable, these AE can still have health-economic implications, affecting the cost-effectiveness of vaccines. A review revealed that only 25 % of recent hea...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Vaccine Ročník 61; s. 127341
Hlavní autori:	Luyten, Jeroen, van Hoek, Albert Jan
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier Ltd 13.08.2025 Elsevier Limited
Predmet:	Adverse events Allergy and Immunology childhood Children Cost analysis Cost effectiveness Cost-Benefit Analysis Data collection Decision making Drug-Related Side Effects and Adverse Reactions - economics Economic evaluation Economics Guillain-Barre syndrome HTA Human papillomavirus Humans Immunization medicine Response rates Rotavirus Side effects surveys Surveys and Questionnaires Vaccination Vaccination - adverse effects Vaccination - economics Vaccines Vaccines - adverse effects Vaccines - economics Viruses Europe Side effects HTA Cost-effectiveness Vaccination Economic evaluation
ISSN:	0264-410X, 1873-2518, 1873-2518
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Although vaccines must adhere to the strictest safety standards in medicine, adverse events (AE) do occur occasionally. Even when clinically negligeable, these AE can still have health-economic implications, affecting the cost-effectiveness of vaccines. A review revealed that only 25 % of recent health-economic studies on childhood vaccines incorporated AE. In this study, we reached out to all corresponding authors of the reviewed articles who excluded AE to understand their rationale for exclusion (response rate 40 % (27/67)). The predominant reasons for not including AE were (1) that these were deemed too rare and insufficiently relevant (17/27, 65 %), (2) analysts adhered to previous methodologies that excluded AE (10/27, 35 %) and (3) there was a lack of sufficient data (9/27, 33 %). We argue that AE deserve more attention from analysts and that more efforts are needed to develop conceptual methods and collect data that enable meaningful incorporation in CEAs. •AE are excluded from most economic evaluations of (childhood) vaccines.•We investigated the reasons behind exclusion in a sample of authors of recent studies.•The most important reason stated was that AE were deemed to be irrelevant for cost-effectiveness.•We argue that AE can be an important factor of cost-effectiveness and must be analysed.•More research is needed to collect better data to enable a meaningful quantification of AE.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	0264-410X 1873-2518 1873-2518
DOI:	10.1016/j.vaccine.2025.127341